Les Funtleyder, health care strategist of Miller Tabak, told CNBC that investors can benefit from certain health care companies that will be boosted by the stimulus package. UPDATE: THE TRIPLE TOP WAS JUST TOO DIFFICULT FOR ILMN TO BREAKTHROUGH. OUR ORIGINAL SHORT TERM PROFIT THESIS HAS BEEN VIOLATED. LET'S SELL FOR A 2% LOSS AND LOOK FOR PROFITS ELSEWHERE. “We’re just looking at fundamentals rather than macro,” he told CNBC. “We’re looking specifically at the genetic analysis space like the Illuminas and Luminexes of the world.” My latest pick and a stock I bought on Friday, May 2, 2009 is Illumina. In the video below I explain my reasoning and how a triple top breakout play could make us a lot of money in this stock.